ESTRO 2025 - Abstract Book

S508

Clinical - Breast

ESTRO 2025

related to a specific scenario of a patient with a low-risk 2 nd iBCE 10 years after the primary. The survey was sent to breast cancer survivors. All information provided was anonymized.

Results: From July 24 to September 24, 105 patients answered the online survey. Regarding demographic data, the most common patient profile was a white (76%), married (61.5%), Christian (58.8%), US-resident (70.2%) woman aged between 61 and 70 (33%), with one additional comorbidity factor (38.6%), working (42.3%) or retired (42.3%) with annual income above 91k €/$. Regarding oncological outcome data, long-term outcomes of SM and 2 nd BCT were perceived as being well established for 51.5% and 17.1% of the responders, respectivelly, while SM and 2 nd BCT were thought to be equally effective for 32.4% (42.9% don’t know). Breast re-irradiation was considered to comprise a risk of complications for 65.7% (28.6% don’t know). 67.3% of patients surveyed had a preference for SM or 2 nd BCT and 65.4% think that one option would be more favourable for a better quality of life; 63% thought that 2 nd BCT provides a more acceptable body self-image. An excellent cosmetic outcome was a top priority for 39.8%. 2 nd BCT was expected to give superior cosmetic outcomes than SM with breast reconstruction for 55.4%. Having enough information and ample time to consider the pros and cons of treatment options were very important/important for 99% and 96.2%, respectively. Treatment choice was not influenced by financial concerns for 68.3%. Conclusion: Patient’s perspective is very important in the decision-making process regarding salvage treatments. Physicians must provide clear, precise information in a timely manner enabling patients to choose the treatment that meets best their expectations Poster Discussion Local management of second breast cancer event after primary breast conserving therapy: International DELPHI consensus Jean-Michel Hannoun-Levi 1 , Julie Margenthaler 2 , Youssef Zeidan 3 , Rosa Di Micco 4 , Isabel Rubio 5 , Jessica Gahm 6 , Bethany Anderson 7 , Frederick Dirbas 8 1 Radiation Oncology, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France. 2 Surgical Oncology, Washington University, Washington, USA. 3 Radiation Oncology, Baptist Health South Florida, Boca Raton, USA. 4 Breast Surgery, IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Milan, Italy. 5 Breast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Spain. 6 Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden. 7 Radiation Oncology, University of Wisconsin, Madison, USA. 8 Surgery, Stanford University School of Medicine, Stanford, USA Purpose/Objective: Most patients who develop a second ipsilateral breast cancer event (2 nd iBCE) after primary breast conserving treatment (BCT) undergo salvage mastectomy (SM). However, some prefer a 2 nd BCT. Given the challenges to perform a randomized clinical trial comparing SM versus 2 nd BCT, an international DELPHI consensus for 2 nd iBCE management was conducted to provide guidance for consideration of a 2 nd BCT. Material/Methods: In February 2023, representative physicians of surgical and radiation oncology breast cancer scientific societies initiated a 2 nd iBCE management survey. After three preparatory rounds (04/23, 10/23 and 12/23), questions were validated and divided into four themes: demographics, 2 nd iBCE selection criteria, 2 nd iBCE therapeutic management (general questions, breast/axillary surgery, re-irradiation), and specific clinical situations. Keywords: breast cancer recurrence, Patient’s perspective 2101